Pasithea Therapeutics (KTTA) said Thursday that interim data from a phase 1 study showed that its experimental drug, PAS-004, was effective and safe in treating neurofibromatosis type 1 and other cancer indications.
Shares surged more than 47% as intraday trading volume climbed to more than 53 million from a daily average of under 18,000.
Telesis Bio (TBIO) disclosed a partnership with Beckman Coulter Life Sciences late Wednesday to set up scalable bio-foundries to deliver on-premise DNA synthesis.
Shares jumped 40% in recent trading Thursday as intraday trading volume soared to over 23.2 million from a daily average of nearly 1.1 million.
Micron Technology (MU) late Wednesday swung to a bigger-than-expected profit for fiscal Q4 as mounting demand for artificial intelligence propelled the memory and storage product maker's revenue above Wall Street's estimates.
Shares climbed more than 13% Thursday, with intraday trading volume at over 83.8 million compared with a daily average of about 24.3 million.
Price: 5.68, Change: +1.83, Percent Change: +47.70
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。